Ameriprise
CNTA

Ameriprise’s Centessa Pharmaceuticals CNTA Stock Holding History

Ameriprise’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$671K Sell
16,893
-263,227
-94% -$6.73M ﹤0.01% 3467
2025
Q4 		$7.01M Buy
280,120
+172,118
+159% +$4.36M ﹤0.01% 2188
2025
Q3 		$2.62M Buy
+108,002
New +$1.92M ﹤0.01% 2866
2025
Q2 		– Sell
-40,868
Closed -$588K – 3988
2025
Q1 		$588K Buy
40,868
+21,746
+114% +$356K ﹤0.01% 3424
2024
Q4 		$320K Buy
+19,122
New +$317K ﹤0.01% 3697

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Ameriprise's CNTA Position: Q1 2026 in Review

Ameriprise reduced its Centessa Pharmaceuticals (CNTA) stake by 94% in Q1 2026, selling an estimated $6.73M and leaving 16,893 shares worth $671K. The position accounts for ﹤0.01% of the portfolio, ranked #3467.

Ameriprise first reported a position in CNTA in Q4 2024 and has held it in 5 quarters since. The position peaked at $7.01M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Ameriprise held 16,893 shares of Centessa Pharmaceuticals worth $671K as of Q1 2026.
  • Ameriprise sold 263,227 Centessa Pharmaceuticals shares in Q1 2026, an estimated $6.73M.
  • Centessa Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3467 holding.
  • Ameriprise first reported a position in Centessa Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Ameriprise's Centessa Pharmaceuticals position peaked at $7.01M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.